GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » Capex-to-Operating-Cash-Flow

XSNX (Novaccess Global) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Novaccess Global Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Novaccess Global's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $-0.06 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Novaccess Global Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Novaccess Global's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novaccess Global Capex-to-Operating-Cash-Flow Chart

Novaccess Global Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novaccess Global Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Novaccess Global's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Novaccess Global's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novaccess Global's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novaccess Global's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Novaccess Global's Capex-to-Operating-Cash-Flow falls into.



Novaccess Global Capex-to-Operating-Cash-Flow Calculation

Novaccess Global's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Sep. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.625
=N/A

Novaccess Global's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.061
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novaccess Global  (OTCPK:XSNX) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Novaccess Global Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Novaccess Global's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Novaccess Global Business Description

Traded in Other Exchanges
N/A
Address
8485 E,Washington Street, No. 127, Chagrin Falls, OH, USA, 44023
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
Executives
Jason Michael Anderson director 8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini director 880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird officer: Chief Financial Officer
Larry Michael Yukich officer: Chief Financial Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin officer: Chief Executive Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc. 10 percent owner 8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin director, 10 percent owner, officer: Chief Executive Officer 8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak director
Osmund Mark Fundingsland director 1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson director 2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt officer: CFO 10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes officer: COO 6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich director, 10 percent owner, officer: President 23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian director, officer: Secretary 626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich director, officer: President 1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404